1. Potential European approval for illuvien still possible (possible) 2. Illuvien for Uveitis (100% ownership) and retisert already approved on much worse data set. (possible) 3. Illuvien for Glucoma. (It causes glaucoma, so wrong) 4. 4th Generation Protein delivery system (possible) 5. Collaboration and licensing deals for illuvien for other parts of the body. (maybe don't see an application for it) 6. Biosilicone (long way from commercilisation)
7. 21 mil in cash I will take your word for it haven't checked.
PVA Price at posting:
$2.10 Sentiment: Sell Disclosure: Not Held
